- Company name
- UnitedHealth Group
- Sector
- Health insurance & managed care
- About
- UnitedHealth Group sells health insurance plans through UnitedHealthcare. This includes Medicare Advantage plans for older adults, and group health plans for employers. Optum, the company's other segment, runs pharmacy benefit management, physician clinics, and health data services. The company earns money mainly from insurance premiums, and from fees for Optum's services.
- Thesis
- UnitedHealth's 2025 cost spike, mainly in Medicare Advantage, forced a guidance withdrawal and a CEO change. It left the market pricing the stock as though the business is still troubled. The medical care ratio has since improved for several straight quarters. The case for a re-rating rests on that trend continuing rather than reversing. It also rests on the outcome of the Department of Justice's investigation into Medicare Advantage billing. A large fine or a forced change to risk-coding practices would cut future revenue. A resolution with limited financial impact would remove a source of negative attention that has weighed on the stock since 2024. New management is also selling down stakes in underperforming clinics, such as a September 2026 deal with TPG for Florida clinics, and cutting prior-authorization requirements starting October 2026. Both steps are meant to show the business model still works without the practices under scrutiny. The next Q3 2026 results, due October 13, 2026, will show whether the medical care ratio keeps improving into the back half of the year. If it does, and the DOJ matter resolves without a severe penalty, the discount can close over the next two to four quarters. If a large fine or forced billing changes arrive instead, the market's caution would prove correct, and the stock could stay discounted well into 2027.
- Risks
- The Department of Justice is running investigations into UnitedHealth's Medicare Advantage billing practices. A Senate investigation published in January 2026 found evidence that the company used home visits and chart reviews to add diagnoses that increased its government payments. A large fine or forced change to these practices could reduce future revenue.
UnitedHealth's medical cost ratio was elevated through 2025 because new Medicare Advantage members cost more to treat than the company priced for. Government rate-setting and shifts in member mix can still push costs higher than planned in future years.
The killing of a UnitedHealthcare executive in December 2024 triggered public anger at health insurers over claim denials and prior authorization. This raised the risk of new state or federal regulation on insurer practices, which could reduce UnitedHealth's margins.
- Balance sheet
- UnitedHealth borrows at the parent holding company, mostly through senior unsecured notes. Total debt was $73.3 billion at June 30, 2026. Of this, $3.8 billion was due within one year, and no commercial paper was outstanding. Cash and short-term investments were $31.5 billion. But most of this cash sits in regulated insurance subsidiaries. These subsidiaries must keep minimum statutory capital and need state approval for large dividends. The parent itself held only $303 million of cash at December 31, 2025. In 2025, it put a net $535 million into these subsidiaries and received no net dividends from them. Debt was 41.2% of total capital at June 30, 2026, down from 44.1% a year earlier. Management targets about 40% by the end of 2026. In the first half of 2026, earnings from operations of $17.0 billion covered interest expense of $1.9 billion about 9 times. $21 billion of bank credit facilities back the commercial paper program, and they were undrawn at December 31, 2025. Moody's (A2), S&P Global (A+) and Fitch (A) all had a negative outlook at June 30, 2026. The debt does not put the business at risk. But the negative outlooks and the reliance on subsidiary dividends explain its choices in the first half of 2026. The company repaid $2.5 billion of debt and kept buybacks to $1.6 billion.
As of 2026-06-30.
- Checkpoints
- Oct 13, 2026: Q3 2026 results: medical care ratio trend. Pending. Watch: A medical care ratio that stays below the year-earlier level and confirmed full-year guidance pass; a rise in the ratio or a guidance cut fails.
Jan 2027 (estimate): Full-year 2026 results and first 2027 earnings outlook. Pending. Watch: A 2027 outlook with earnings growth and debt to capital near 40% passes; a flat or lower outlook or new reserve charges fails.
2027 (estimate): Department of Justice Medicare Advantage billing investigation outcome. Pending. Watch: A settlement with a fine the company can pay from one quarter of cash flow and no forced change to risk coding passes; a large fine or forced coding changes fail.
- Recent events
- 2026-09-29: UnitedHealthcare named Robert Hunter its president. Hunter was CEO of UnitedHealthcare Government Programs. Tim Noel stays CEO of UnitedHealthcare.
2026-09-09: UnitedHealth sold a minority stake in a group of Florida WellMed clinics, which focus on older patients, to private-equity firm TPG. Optum keeps an ownership interest and stays in the local market.
2026-07-16: UnitedHealth reported Q2 2026 revenue of $112.0 billion. The medical care ratio improved to 86.7%, from 89.4% a year earlier, and management raised full-year guidance.
2025-05-13: UnitedHealth withdrew its full-year 2025 earnings guidance. CEO Andrew Witty stepped down, and Stephen Hemsley returned as CEO.